Verition Fund Management LLC Takes $106,000 Position in Inogen, Inc. (NASDAQ:INGN)

Verition Fund Management LLC acquired a new position in shares of Inogen, Inc. (NASDAQ:INGN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,954 shares of the medical technology company’s stock, valued at approximately $106,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Divisadero Street Capital Management LP lifted its stake in shares of Inogen by 682.3% in the second quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock valued at $19,079,000 after buying an additional 2,046,766 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Inogen by 312.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock worth $1,694,000 after acquiring an additional 132,287 shares during the period. AQR Capital Management LLC grew its holdings in shares of Inogen by 29.3% during the 2nd quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock worth $4,642,000 after purchasing an additional 129,307 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Inogen in the second quarter valued at $651,000. Finally, Monaco Asset Management SAM bought a new position in Inogen in the second quarter worth $610,000. Institutional investors own 89.94% of the company’s stock.

Inogen Price Performance

Shares of INGN opened at $8.95 on Tuesday. The business’s 50 day simple moving average is $9.50 and its 200-day simple moving average is $9.73. Inogen, Inc. has a one year low of $5.08 and a one year high of $13.33. The company has a market capitalization of $213.17 million, a P/E ratio of -3.98 and a beta of 1.02.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on INGN shares. StockNews.com raised Inogen from a “hold” rating to a “buy” rating in a report on Thursday, December 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a report on Friday, November 8th.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.